Revenue
Sandoz Revenue
+2.59%
+29.2%
Innovative Medicines Revenue
+0.42%
+4.24%
Revenue by Geography
Asia/Africa/Australasia Revenue (Post-Q2 2023 Reporting)
-0.68%
-6.62%
Europe Revenue (Post-Q2 2023 Reporting)
+2.55%
+28.6%
United States Revenue (Post-Q2 2023 Reporting)
-1.79%
-16.5%
Canada and Latin America Revenue (Post-Q2 2023 Reporting)
-0.88%
-8.42%
Revenue by Geography
Asia/Africa/Australasia Revenue (Pre-Q3 2023 Reporting)
+3.1%
+35.64%
United States Revenue (Pre-Q3 2023 Reporting)
+0.49%
+5.05%
Canada and Latin America Revenue (Pre-Q3 2023 Reporting)
+3.17%
+36.59%
Europe Revenue (Pre-Q3 2023 Reporting)
-1.84%
-16.97%
Revenue
Neuroscience Revenue
+2.72%
+30.84%
Established Brands Revenue
+3.56%
+41.94%
Cardiovascular, Renal And Metabolic Revenue
+0.45%
+4.55%
Immunology Revenue
-1.75%
-16.2%
Oncology Revenue
-0.1%
-1.01%
Gross Profit
Innovative Medicines Gross Profit
+0.38%
+3.88%
Corporate Gross Profit
-1.38%
-12.95%
Sandoz Gross Profit
-2.25%
-20.37%
EBIT
Corporate Operating Profit
+0.11%
+1.07%
Sandoz Operating Profit
+2.85%
+32.51%
Innovative Medicines Operating Profit
+1.29%
+13.64%
